Author(s)

Siyi Wan ¹, Gaiping Wu ¹

Affiliation(s)

¹ Department of Emergency Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China

Corresponding Author

Gaiping Wu

ABSTRACT

The adenosine metabolic pathway is a key player in molecular interactions that control physiological processes, complexly regulating immune response, inflammation, and vital functions. Enzymes like CD39 and CD73 regulate the balance between ATP, ADP, and adenosine, affecting a variety of biological processes. Purinergic signaling is mediated by P1/ adenosine and P2 receptors and influences immune cells such as neutrophils, mononuclear macrophages, dendritic cells, and lymphocytes to form their bidirectional function. The complex dance of purinergic signaling extends its influence on thrombosis, graft rejection, and biological barrier function. In diseases such as thrombosis and graft rejection, dysregulation of CD39 activity may lead to vascular damage and inflammation. In addition, ATP and adenosine have been found to play a role in tumor progression, affecting immune cell subsets and showing potential for therapeutic intervention. By understanding the adenosine metabolic pathway, we can gain insight into its multiple effects on health and disease, paving the way for future biomedical research.

KEYWORDS

ATP; Adenosine; Purinergic Receptors; Immune Regulation

CITE THIS PAPER

Siyi Wan, Gaiping Wu, The Function of eATP/Adenosine Metabolism in Immune Modulation. MEDS Clinical Medicine (2023) Vol. 4: 9-14. DOI: http://dx.doi.org/10.23977/medsc.2023.040902.

REFERENCES

[1] C S R, Jean S, Herbert Z. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance.[J]. Purinergic signalling, 2006, 2(2). 
[2] Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacological reviews 1998; 50(3): 413-492.
[3] Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends in neurosciences 2009; 32(1): 19-29.
[4] Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. The New England journal of medicine 2012; 367(24).
[5] Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature 2014; 509(7500).
[6] Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacology & therapeutics 2006; 112(2): 358-404.
[7] Massé K, Dale N. Purines as potential morphogens during embryonic development. Purinergic signalling 2012; 8(3).
[8] Burnstock G, Ralevic V. Purinergic signaling and blood vessels in health and disease. Pharmacological reviews 2014; 66(1).
[9] Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic signalling 2008; 4(1): 1-20.
[10] Lohman AW, Billaud M, Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovascular research 2012; 95(3).
[11] Yegutkin GG. Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Critical reviews in biochemistry and molecular biology 2014; 49(6)
[12] Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiological reviews 2007; 87(2): 659-797.
[13] Junger WG. Immune cell regulation by autocrine purinergic signalling. Nature reviews Immunology 2011; 11(3).
[14] Cekic C, Linden J. Purinergic regulation of the immune system. Nature reviews Immunology 2016; 16(3).
[15] Burnstock G. Purine and purinergic receptors. Brain and neuroscience advances 2018; 2: 2398212818817494.
[16] Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochimica et biophysica acta 2008; 1783(5).
[17] Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunological reviews 2017; 276(1).
[18] Zimmermann H, Zebisch M, Sträter N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic signalling 2012; 8(3): 437-502.
[19] Boison D, Yegutkin GG. Adenosine Metabolism: Emerging Concepts for Cancer Therapy. Cancer cell 2019; 36(6).
[20] Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proceedings of the National Academy of Sciences of the United States of America 2001; 98(12).

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine